Asaf Danziger
Chief Executive Officer at NovoCure Limited
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: NovoCure Limited, 3 years.
NovoCure Limited
Director · Chief Executive Officer
Chief executive roles
NovoCure Limited
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | NovoCure Limited | Grant or award | +268 | $11.15 | $2,988 |
| Dec 31, 2025 | NovoCure Limited | Grant or award | +1 | $10.99 | $11 |
| Jun 30, 2025 | NovoCure Limited | Grant or award | +833 | $15.13 | $12,603 |
| Jan 1, 2025 | NovoCure Limited | Grant or award | +400,000 | — | — |
| Dec 31, 2024 | NovoCure Limited | Grant or award | +412 | $14.75 | $6,077 |
| Jun 28, 2024 | NovoCure Limited | Grant or award | +1,239 | $12.24 | $15,165 |
| Jun 30, 2023 | NovoCure Limited | Grant or award | +367 | $35.28 | $12,948 |
| Jan 6, 2023 | NovoCure Limited | Grant or award | +39 | $62.31 | $2,430 |
| Jan 5, 2023 | NovoCure Limited | Option exercise | +25,000 | $11.46 | $286,500 |
| Jan 5, 2023 | NovoCure Limited | Open-market sale | −8,369 | $111.23 | $930,884 |
| Jan 5, 2023 | NovoCure Limited | Open-market sale | −2,000 | $112.86 | $225,720 |
| Jan 5, 2023 | NovoCure Limited | Open-market sale | −4,568 | $114.35 | $522,351 |
| Jan 5, 2023 | NovoCure Limited | Open-market sale | −3,702 | $115.21 | $426,507 |
| Jan 5, 2023 | NovoCure Limited | Open-market sale | −1,395 | $116.06 | $161,904 |
| Jan 5, 2023 | NovoCure Limited | Open-market sale | −999 | $117.01 | $116,893 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.